文献速递病毒性肝炎

基于RT-LAMP联合CRISPR-Cas12b的丙型肝炎病毒RNA快速检测方法

A Rapid Assay for Hepatitis C Virus RNA Detection Using Reverse-Transcription Loop-Mediated Isothermal Amplification-Coupled CRISPR-Cas12b-Based Strategy.
PubMed 文献 · J Infect Dis · 2026-01-01

研究开发了一种将逆转录环介导等温扩增(RT-LAMP)与CRISPR-Cas12b荧光读数结合的HCV RNA快速检测方法。该方法可检测基因1a、1b、2、3a和4型HCV RNA,使用500 μL血浆时基因1型≥100 IU/mL可在40-45分钟内检出,基因3型最低检测限为5000 IU/mL。在72例HCV患者样本中临床敏感性为100%,在33例HCV阴性样本中特异性为100%。

要点

  • 基因1型HCV RNA≥100 IU/mL可在40-45分钟内检出,基因3型最低检测限为5000 IU/mL。
  • 72例HCV患者样本临床敏感性100%,33例阴性样本特异性100%,无假阳性。
  • 该方法可直接从血浆检测HCV RNA,有望用于资源有限地区的筛查和诊断。

核心结论

  • RT-LAMP联合CRISPR-Cas12b方法可在45分钟内直接从血浆检测HCV RNA,具有高敏感性和特异性,有望用于全球HCV感染的高效筛查和诊断。

研究设计与样本

  • 从血浆提取RNA后,用HCV特异性引物进行逆转录和环介导等温扩增,扩增产物通过CRISPR-Cas12b荧光读数检测。
  • 使用HCV JFH1质粒(基因2型)确定最低检测限,并在临床样本中确定基因1型和3型的最低检测限。
  • 临床样本包括72例HCV患者样本(含急性HCV和HCV/HBV合并感染)和33例HCV阴性样本(含HBV或HIV/HBV合并感染)。

主要发现

  • 可检测基因1a、1b、2、3a和4型HCV RNA,具有高敏感性和特异性。
  • HCV JFH1质粒(基因2型)最低检测限为250质粒拷贝/mL(约100 IU/mL)。
  • 使用500 μL血浆时,基因1型RNA≥100 IU/mL在40-45分钟内检出,基因3型最低检测限为5000 IU/mL。
  • 72例HCV患者样本临床敏感性为100%,33例HCV阴性样本特异性为100%,无假阳性。

关键数值与推荐

  • HCV JFH1质粒(基因2型)最低检测限:250质粒拷贝/mL(约100 IU/mL)。
  • 使用500 μL血浆,基因1型RNA≥100 IU/mL在40-45分钟内检出。
  • 基因3型最低检测限:5000 IU/mL。
  • 72例HCV患者样本临床敏感性100%;33例HCV阴性样本特异性100%,无假阳性。

临床怎么用

  • 该方法可在45分钟内直接从血浆检测HCV RNA,适合用于边缘化和偏远人群的筛查。
  • 高特异性和敏感性支持其作为HCV感染的快速筛查和诊断工具。
  • 使用500 μL血浆,检测基因1型灵敏度较高(≥100 IU/mL),但基因3型最低检测限为5000 IU/mL,需注意基因型差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) diagnosis usually requires detection of antibody followed by HCV RNA. The requirement for 2 tests leads to major drop-offs in the cascade of care. Existing near-care HCV RNA tests have slow turnaround time and are expensive with limited availability. We aim to develop a cost-effective, rapid, and sensitive test for detection of HCV RNA to enhance screening, particularly in marginalized and remote populations. METHODS: After RNA extraction from plasma, HCV RNA is reverse-transcribed and amplified using loop-mediated isothermal amplification with HCV-specific primers. The amplified HCV DNA is then detected via CRISPR-Cas12b with a fluorescence readout. RESULTS: HCV RNA from patient samples with genotypes 1a, 1b, 2, 3a, and 4 was detected with high sensitivity and specificity. The lower limit of detection (LLOD) with HCV JFH1 plasmid (genotype 2) is 250 plasmid copies/mL (approximately 100 IU/mL). For clinical samples, we determined the LLOD for genotypes 1 and 3, the most common in North America. Using 500 μL of plasma, genotype 1 RNA ≥100 IU/mL was detected within 40-45 minutes, while genotype 3 had an LLOD of 5000 IU/mL. The clinical sensitivity was 100% in 72 HCV patient samples, including acute HCV and HCV/hepatitis B virus (HBV) coinfection. The specificity was 100%, with no false-positives in 33 HCV-negative samples, including those with HBV or human immunodeficiency virus/HBV coinfection. CONCLUSIONS: Our assay shows high specificity and sensitivity to detect HCV RNA directly from plasma within 45 minutes and hence could be used for efficient screening and diagnosis of HCV infection globally.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chowdhury A, Garcia BG, Zahoor MA, et al. A Rapid Assay for Hepatitis C Virus RNA Detection Using Reverse-Transcription Loop-Mediated Isothermal Amplification-Coupled CRISPR-Cas12b-Based Strategy. J Infect Dis. 2026. PMID: 41397899. doi:10.1093/infdis/jiaf609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。